Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prometic IGIV 10% in Primary Immunodeficiency
NCT02269163Phase 3Completed
- Sponsor
- Prometic Biotherapeutics Ltd
- Start
- Jan 2016
- Primary completion
- Jan 2019
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of Prometic IGIV in primary immunodeficiency disease (PID), sponsored by Prometic Biotherapeutics Ltd. Started Jan 2016; status: completed.
02
Drugs
Prometic IGIV
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT02269163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269163.